Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

[1]  Timothy A. Miller,et al.  Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2022, The New England journal of medicine.

[2]  S. Tabrizi,et al.  Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities , 2022, The Lancet Neurology.

[3]  Anonymous,et al.  2021 Alzheimer's disease facts and figures , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  P. Edison,et al.  Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? , 2020, Nature Reviews Neurology.

[5]  Nick C Fox,et al.  BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. , 2020, Brain : a journal of neurology.

[6]  Timothy A. Miller,et al.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.

[7]  E. Sigurdsson,et al.  Tau immunotherapies: Lessons learned, current status and future considerations , 2020, Neuropharmacology.

[8]  2020 Alzheimer's disease facts and figures , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[9]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[10]  R. Barker,et al.  Targeting Huntingtin Expression in Patients with Huntington's Disease. , 2019, The New England journal of medicine.

[11]  K. Blennow,et al.  Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[12]  R. Bateman,et al.  Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.

[13]  Derek H. Oakley,et al.  Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain , 2018, Front. Neurosci..

[14]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[15]  J. Hardy,et al.  Alzheimer's disease , 2018, European journal of neurology.

[16]  J. Seibyl,et al.  APPLICATION OF A MULTI-ATLAS SEGMENTATION TOOL TO HIPPOCAMPUS, VENTRICLE AND WHOLE BRAIN SEGMENTATION , 2017, Alzheimer's & Dementia.

[17]  K. Schoch,et al.  Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases , 2017, Neuron.

[18]  J. Dukart,et al.  Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD) , 2017, Journal of Alzheimer's disease : JAD.

[19]  Keith A. Johnson,et al.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.

[20]  M. Jorge Cardoso,et al.  A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset , 2017, Neuroinformatics.

[21]  Timothy A. Miller,et al.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy , 2017, Science Translational Medicine.

[22]  Timothy A. Miller,et al.  Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model , 2016, Neuron.

[23]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[24]  Nick C Fox,et al.  Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[25]  D. Holtzman,et al.  Analysis of in vivo turnover of tau in a mouse model of tauopathy , 2015, Molecular Neurodegeneration.

[26]  B. Hyman,et al.  Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain , 2015, Nature Communications.

[27]  S. Paul,et al.  Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody , 2015, Scientific Reports.

[28]  P. Verstreken,et al.  Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. , 2015, Cell reports.

[29]  D. Arnold,et al.  Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients , 2015, Multiple sclerosis.

[30]  E. Roberson,et al.  Seizure resistance without parkinsonism in aged mice after tau reduction , 2014, Neurobiology of Aging.

[31]  Evan T. Geller,et al.  Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies , 2014, Molecular therapy. Nucleic acids.

[32]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[33]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[34]  Meaghan Morris,et al.  Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice , 2013, Neurobiology of Aging.

[35]  Sebastien Ourselin,et al.  Cerebral atrophy in mild cognitive impairment and Alzheimer disease , 2013, Neurology.

[36]  V. Laporte,et al.  Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.

[37]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[38]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[39]  P. Tariot,et al.  A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.

[40]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[41]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[42]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[43]  Kai Zhang,et al.  Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport , 2010, Science.

[44]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[45]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[46]  R. Bartha,et al.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. , 2008, Brain : a journal of neurology.

[47]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[48]  Ram Dixit,et al.  Differential Regulation of Dynein and Kinesin Motor Proteins by Tau , 2008, Science.

[49]  A. Harada,et al.  14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice , 2007, Neuroreport.

[50]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[51]  L. Qiang,et al.  Tau Protects Microtubules in the Axon from Severing by Katanin , 2006, The Journal of Neuroscience.

[52]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[53]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[54]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[55]  L. Thal,et al.  Clinical Dementia Rating training and reliability in multicenter studies , 1997, Neurology.

[56]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[57]  Nick C Fox,et al.  Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[58]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.